...
首页> 外文期刊>Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences >In silico study of naphtha (1, 2-d) thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.
【24h】

In silico study of naphtha (1, 2-d) thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.

机译:在石脑油(1,2-d)噻唑-2-胺与腺苷A 2A受体的计算机研究中及其在氟哌啶醇诱导的小鼠运动障碍的拮抗作用中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Loss of dopaminergic nigrostriatal neurons in the substantia nigra leads to Parkinson's disease (PD). Adenosine A(2A) receptors (A(2A)Rs) have been anticipated as novel therapeutic target for PD. A(2A)Rs potentiate locomotor behavior and are predominantly expressed in striatum. Naphtha [1, 2-d] thiazol-2-amine (NATA), a tricyclic thiazole have been studied as new anti-Parkinsonian compound. AutoDock analysis and pharmacophore study of NATA with known A(2A)R antagonists explicit its efficacy as a possible adenosine receptor antagonist. In vivo pharmacology of NATA showed reduction of haloperidol (HAL)-induced motor impairments in Swiss albino male mice. Relatively elevated levels of dopamine in NATA pre-treated mice are suggestive of its possible role as neuromodulator in PD.
机译:黑质中多巴胺能黑质纹状体神经元的丢失会导致帕金森氏病(PD)。腺苷A(2A)受体(A(2A)Rs)被认为是PD的新型治疗靶标。 A(2A)Rs增强运动行为,并主要在纹状体中表达。石脑油[1,2-d]噻唑-2-胺(NATA),一种三环噻唑已被研究为新型抗帕金森病化合物。使用已知的A(2A)R拮抗剂对NATA进行AutoDock分析和药效基团研究,明确了其作为可能的腺苷受体拮抗剂的功效。 NATA的体内药理学研究表明,瑞士白化病雄性小鼠中氟哌啶醇(HAL)引起的运动障碍减少。在NATA预处理的小鼠中,多巴胺的水平相对升高表明它可能在PD中作为神经调节剂发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号